Yazar "Karagol, H." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The effect of serum ADMA levels on infarct volume and prognosis in patients with acute ischemic stroke(Elsevier Science Bv, 2009) Salam, F.; Celik, Y.; Karagol, H.; Balci, K.; Asil, T.[Abstract Not Available]Öğe Prognostic factors for renal cell carcinoma: Trakya University experience from Turkey(Wiley, 2010) Yurut-Caloglu, V.; Caloglu, M.; Kaplan, M.; Oz-Puyan, F.; Karagol, H.; Ibis, K.; Cosar-Alas, R.The purpose of the present study is to evaluate the prognostic factors of patients with renal cell carcinoma. The treatment results such as distant metastasis-free survival and overall survival of 59 previously untreated patients were retrospectively analysed. Median follow-up was 17.5 months (3.8-88.5 months). Overall survival was 22.4 months (3-87 months). Distant metastasis developed in 35 (59%) patients. The Eastern Cooperative Oncology Group (ECOG) performance status (P = 0.022), tumour size (P = 0.025) and lymphatic invasion (P < 0.0001) were significantly effective prognostic factors for distant metastasis-free survival on multivariate analysis. Related to overall survival, gender (P = 0.025), ECOG performance status (P = 0.027), nuclear grade (P = 0.002), tumour size (P = 0.029), T stage (P = 0.044), nodal involvement (P = 0.003), surgical margin (P = 0.046), renal sinus invasion (P < 0.0001), perineural growth (P = 0.001) and lymphatic invasion (P < 0.0001) were significant prognostic factors on univariate analysis. Gender (P = 0.008), ECOG performance status (P = 0.027), tumour size (P = 0.025) and lymphatic invasion (P < 0.0001) retained their significance on multivariate analysis. We concluded that the most important prognostic factors for patients with renal cell carcinomas are ECOG performance status, tumour size and lymphatic invasion.Öğe Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience(Imprimatur Publications, 2009) Caloglu, M.; Yurut-Caloglu, V.; Karagol, H.; Bayir-Angin, G.; Turan, F. N.; Uzal, C.Purpose: To evaluate the survival of patients with glioblastoma multiforme (GBM) and analyse the prognostic Actors influencing survival. Patients and methods: Seventy-eight consecutive patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ) (in 21 patients) between 1999 and 2006 were retrospectively analysed. Results: Sixty-seven (85.5%) patients had undergone gross total or subtotal resection before RT The median overall survival was 9.8 months, and significantly influenced by age (p=0.02), Karnofsky performance status (p=0.001), RT (p<0.0001), gender (p=0.02), concomitant TMZ (p=0.003), RT waiting time (p=0.014), and treatment time (p=0.01) in univariate analysis. In multivariate analysis, older age (p=0.03), male gender (p=0.01), absence of concomitant TMZ (p=0.008), RT dose below 60 Gy (p=0.03), RT waiting time more than 20 days (p=0.01), and treatment time more than 76 days (p=0.0072) were poor prognosticators. Conclusion: This study emphasizes the importance of female gender, dose and duration of RT and RT waiting time in patients with glioblastoma multiforme.